1 12 November 2020
2 EMA/CHMP/802679/2018 Rev.1* Corr.1**
3 Committee for Medicinal Products for Human Use (CHMP)

4 Palbociclib hard capsule 75 mg, 100 mg and 125 mg and 5 film-coated tablet 75 mg, 100 mg and 125 mg product-6 specific bioequivalence guidance

7 Draft

Draft Agreed by Pharmacokinetics Working Party (PKWP)	October 2018
Adopted by CHMP for release for consultation	31 January 2019
Start of public consultation	8 February 2019
End of consultation (deadline for comments)	30 June 2019
Draft Agreed by Pharmacokinetics Working Party (PKWP)	September 2019
Adopted by CHMP	19 September 2019
Date of coming into effect	1 April 2020
Draft revision agreed by Pharmacokinetics Working Party	October 2020
Adopted by CHMP for release for consultation	12 November 2020
Start of public consultation	23 November 2020
End of consultation (deadline for comments)	28 February 2021
Agreed by Pharmacokinetics Working Party	
Adopted by CHMP	
Date of coming into effect	

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

* This revision concerns the addition of requirements for a tablet.

** Corr.1 - Reference number has been corrected and should read "EMA/CHMP/802679/2018 Rev.1*"

Comments should be provided using this template. The completed comments form should be sent to PKWPsecretariat@ema.europa.eu

Keywords	***Bioequivalence, generics, palbociclib***

Palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (PKWP)*

BCS Classification**	**BCS Class:** ☐ **I** ☐ **III** ☒ **Neither of the two** **Background:** Palbociclib is considered a low solubility compound.
Bioequivalence study design *in case a BCS biowaiver is not feasible or applied*	**single dose** **cross-over**
	healthy volunteers
	Capsules: ☐ **fasting** ☒ **fed** ☐ **both** ☐ **either fasting or fed** Tablets:

	☒ **fasting** ☐ **fed** ☐ **both** ☐ **either fasting or fed** In addition to the regular study under fasting conditions a fasting study under conditions of multiple day pre-treatment with a proton pump inhibitor (PPI), such as pantoprazole (40 mg b.i.d. for 4 days), should be conducted. **Background:** Solubility of palbociclib is pH dependent. PPIs may affect the bioavailability of palbociclib under fasting conditions differently depending on the formulation.
	Strength: 125 mg **Background:** Highest strength for drugs with linear pharmacokinetics and low solubility.
	Number of studies: Capsules: One single-dose study (fed state) Tablets: Two single-dose studies (fasting and under conditions of pre-treatment with a PPI).
Analyte	☒ **parent** ☐ **metabolite** ☐ **both**
	☒ **plasma/serum** ☐ **blood** ☐ **urine**
	Enantioselective analytical method: ☐ **yes** ☒ **no**
Bioequivalence assessment	**Main pharmacokinetic variables:** $AUC_{0\text{-}72h}$, C_{max}
	90% confidence interval: 80.00 – 125.00%

* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C_{max}. If high intra-individual variability (CV_{intra} > 30%) is expected, the applicants might follow respective guideline recommendations.

** This tentative BCS classification of the drug substance serves to define whether *in vivo* studies seems to be mandatory (BCS class II and IV) or, on the contrary (BCS Class I and III), the Applicant may choose between two options: *in vivo* approach or *in vitro* approach based on a BCS biowaiver. In this latter case, the BCS classification of the drug substance should be confirmed by the Applicant at the time of submission based on available data (solubility experiments, literature, etc.). However, a BCS-based biowaiver might not be feasible due to product specific characteristics despite the drug substance being BCS class I or III (e.g. *in vitro* dissolution being less than 85% within 15 min (BCS class III) or 30 min (BCS class I) either for test or reference, or unacceptable differences in the excipient composition).